Claudia Collu

Dr. Claudia Collu

U.O. di Pneumologia Ospedale San Martino di Oristano
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AZAngelo Zinellu
Angelo Zinellu
CCClaudia Collu
Claudia Collu
MNMouhamad Nasser
Mouhamad Nasser
Panagiotis PaliogiannisPanagiotis Paliogiannis
Panagiotis Paliogiannis
SMSabrina Mellino
Sabrina Mellino
Vincent CottinVincent Cottin
Vincent Cottin
Variable patterns of disease progression are typically observed in patients with idiopathic pulmonary fibrosis (IPF). We sought to determine the prognostic capacity of blood cell count indexes, derived from routine complete blood cell (CBC) count, in a cohort of IPF patients. The neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were calculated at baseline in a consecutive series of 82 IPF patients followed for four years. After adjusting for age, gender, body mass index, smoking status, and disease stage, only the AISI was significantly associated with mortality (HR 1.0013, 95% CI 1.0003–1.0023, p = 0.015). Patients with AISI <434 and ≥434 had a median survival from the diagnosis of 35.3 ± 15.2 and 26.6 ± 16.3 months (p = 0.015), and a four-year survival rate of 54% and 34%, respectively. The AISI, easily derivable from routine laboratory tests, is independently associated with mortality in patients with IPF. Prospective studies in larger cohorts are required to confirm this association.

25 August 2020 in Lung
Verified
Journal Article
Open access
PDF file
AZAngelo Zinellu
Angelo Zinellu
Panagiotis PaliogiannisPanagiotis Paliogiannis
Panagiotis Paliogiannis
ESElisabetta Sotgiu
Elisabetta Sotgiu
SMSabrina Mellino
Sabrina Mellino
AMArduino A. Mangoni
Arduino A. Mangoni
AFAlessandro G. Fois
Alessandro G. Fois
Purpose: Inflammation and immunity play a pivotal but yet unclear role in idiopathic pulmonary fibrosis (IPF), a chronic disorder characterized by progressive damage of lung parenchyma and severe loss of lung function despite optimal treatment. However, the pathophysiological and predictive role of combined blood cell count indexes of inflammation in IPF is uncertain. Methods: Seventy-three patients with IPF and 62 healthy subjects matched for age, gender and smoking status were included in this cross-sectional study. Results: We found significant differences in neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), systemic inflammation response index (SIRI) and aggregate index of systemic inflammation (AISI) between IPF patients and healthy controls. In logistic regression, all combined blood inflammation indexes, barring PLR, were independently associated with the presence of IPF after adjusting for age, gender, body mass index and smoking status. Furthermore, significant associations between FVC% and NLR, LMR, SIRI and AISI, and between DLCO% and NLR, dNLR, LMR, SIRI and AISI, were observed. Conclusions: In conclusion, our data indicate significant alterations of combined blood cell count indexes of inflammation in IPF.

7 September 2018 in Biomarkers in Medicine
Verified
Journal Article
Closed access
Panagiotis PaliogiannisPanagiotis Paliogiannis
Panagiotis Paliogiannis
AFAlessandro G Fois
Alessandro G Fois
CCClaudia Collu
Claudia Collu
ABAntonietta Bandinu
Antonietta Bandinu
EZElisabetta Zinellu
Elisabetta Zinellu
AZAngelo Zinellu
Angelo Zinellu
Aim: The aim of this meta-analysis was to investigate associations between idiopathic pulmonary fibrosis (IPF) and markers of oxidative stress (OS) measured in different biological samples. Methods: A systematic search of publications listed in PubMed, Web of Science, Scopus and Google Scholar from inception to December 2017 was conducted. Results: Significant differences between IPF patients and controls were observed for all biomarkers (thiobarbituric acid reactive substances, hydroperoxides and glutathione), barring systemic isoprostanes. Conclusion: This meta-analysis showed a consistent increase in the concentrations of OS markers or a reduction in antioxidant markers, in patients with IPF, independent of the type of biological sample. Pending the results of further studies, OS biomarkers might be useful for the diagnosis and monitoring of IPF.

1 May 2021 in Chemosphere
Verified
Journal Article
Closed access
GFGiovanni Forte
Giovanni Forte
BBBeatrice Bocca
Beatrice Bocca
APAndrea Pisano
Andrea Pisano
CCClaudia Collu
Claudia Collu
CFCristiano Farace
Cristiano Farace
RMRoberto Madeddu
Roberto Madeddu

1 May 2018 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CCClaudia Collu
Claudia Collu
AFAlessandro Fois
Alessandro Fois
PCPaola Crivelli
Paola Crivelli
GTGianni Tidore
Gianni Tidore
CFClaudio Fozza
Claudio Fozza
PPPietro Pirina
Pietro Pirina
Clinical and radiological manifestations of tuberculosis (TB) are heterogeneous, and differential diagnosis can include both benign and malignant diseases (e.g., sarcoidosis, metastatic diseases, and lymphoma). Diagnostic dilemmas can delay appropriate therapy, favoring Mycobacterium tuberculosis transmission. We report on a case of TB in an immunocompetent, Somalian 22-year-old boy admitted in the respiratory unit of an Italian university hospital. His symptoms and clinical signs were thoracic pain, weight loss, latero-cervical, mediastinal, and abdominal lymphadenopathy. Smear microscopy and PCR were negative for Mycobacterium tuberculosis. The unclear histological pattern, the unusual clinical presentation, the CT scan signs, the BAL lymphocytes suggested the suspicion a lymphoma. Culture conversion proved Mycobacterium tuberculosis infection. This case report highlights the risk of misdiagnosis in patients with generalized lympho-adenopathy and pulmonary infiltrates, particularly in Africans young patients.

5 June 2020 in Primary Health Care Research & Development
Verified
Journal Article
Open access
PDF file
PPPietro Pirina
Pietro Pirina
EZElisabetta Zinellu
Elisabetta Zinellu
MMMarco Martinetti
Marco Martinetti
CSClaudia Spada
Claudia Spada
BPBarbara Piras
Barbara Piras
AFAlessandro Giuseppe Fois
Alessandro Giuseppe Fois
Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that may have a negative impact on both patients’ quality of life and survival. Patients with COPD frequently suffer from heart failure (HF), likely owing to several shared risk factors. Aim: To evaluate the differences in treatment of COPD with and without HF comorbidity according to COPD severity in the general practitioner setting. Methods: We conducted an observational, retrospective study using data obtained from the Italian Health Search Database, which collects information generated by the routine activity of general practitioners. The study sample included 225 patients with COPD, alone or combined with HF. Findings: It has been found that the prevalence of some comorbidities such as diabetes and HF significantly increases with the severity of COPD. Regarding pharmacological treatment, a reduction in the prescription of individually administered long-acting β 2-agonists (LABAs) and long-acting anticholinergics (LAMAs) has been observed with increasing severity of the disease. Moreover, an increase in the prescription of both the combination of the two bronchodilators (LABA + LAMA) and their association with inhaled corticosteroids has been observed with increasing severity of COPD. The prescription of β-blockers in patients with COPD suffering from HF comorbidity decreases from 100% in stage I to less than 50% in the other stages of COPD. This study shows that general practitioners do not follow the guidelines recommendations for the management of patients with COPD in the different stages of the disease, with and without HF comorbidity, as well as in the management of HF. Further efforts must be made to ensure adequate treatment for these patients.